Maravai Lifesciences reports Q4 adjusted EPS (4c), consensus (7c)

Reports Q4 revenue $49.9M, consensus $48.75M. “Driven by strong execution across the organization, we exceeded our revenue expectations and returned to positive Adjusted EBITDA in the fourth quarter, underscoring the operating leverage of our new model,” said Bernd Brust, CEO, Maravai LifeSciences (MRVI). Brust continued, “We enter 2026 well positioned to drive operational excellence, accelerate revenue growth, and continue improving Adjusted EBITDA as we work toward creating long-term value for all stakeholders.”